GLP-1 drugs like Zepbound, Ozempic, and Wegovy dominate headlines, but Medicare's rules are nuanced. Here is what is actually covered in 2026.
Why doesn't Medicare cover Zepbound for weight loss?
By law, Medicare Part D is prohibited from covering any drug used only for weight loss. Zepbound (tirzepatide) is FDA-approved for chronic weight management, so a plan cannot pay for it when that is the sole reason. This restriction dates back to the 2003 Medicare Modernization Act and still applies in 2026. The workaround is medical indication: if Zepbound is prescribed for an approved condition Medicare does cover, such as moderate-to-severe obstructive sleep apnea in adults with obesity, a Part D plan that lists it on its formulary may pay. Coverage is always indication-specific, so the exact diagnosis on your prescription matters. Call 1-800-MEDIGAP to confirm your plan's rules.
What is the 2026 Medicare GLP-1 Bridge program?
Beginning July 1, 2026, CMS launched a temporary demonstration nicknamed the GLP-1 Bridge that, for the first time, gives eligible Medicare Part D members access to Zepbound (KwikPen) for obesity at a flat $50 copay per 30-day supply. The program runs through December 31, 2027. You must be enrolled in a participating Part D plan, and you generally need a BMI of 35 or higher, or a BMI of 30 to 34.99 with a qualifying condition. Important: the $50 copay operates outside the normal Part D benefit, so it does not count toward your deductible or the $2,100 annual out-of-pocket cap, and single-dose vials are excluded.
Which GLP-1 drugs does Medicare cover in 2026?
Medicare Part D can cover GLP-1 drugs when they are prescribed for an approved, non-weight-loss medical use and your plan lists them. Ozempic and Mounjaro may be covered for type 2 diabetes. Wegovy may be covered to reduce the risk of cardiovascular death, heart attack, or stroke in adults with established cardiovascular disease who are overweight or obese. Zepbound may be covered for obstructive sleep apnea. None of these are covered for weight loss alone outside the GLP-1 Bridge. Most plans also apply prior authorization, step therapy, or quantity limits, so two enrollees on the same drug can pay very different amounts.
What will I actually pay for covered drugs in 2026?
In 2026, every Medicare Part D plan caps your annual out-of-pocket spending on covered drugs at $2,100. Once you hit that ceiling, covered prescriptions cost you nothing for the rest of the year. Insulin is capped at $35 (or less) per month with no deductible. Negotiated prices from the Medicare Drug Price Negotiation Program also took effect January 1, 2026; for example, Eliquis dropped to a $231 negotiated 30-day price, a 56% cut versus 2023. Your share still depends on your plan's tier, deductible, and pharmacy. A licensed specialist at 1-800-MEDIGAP can run your exact drug list against plans for free.
How do I find a plan that covers my medications?
The single most important step is matching your specific prescriptions to a plan's formulary before you enroll. Two Part D or Medicare Advantage plans can treat the same drug very differently, one covering it on a low tier and another not at all. Bring your full medication list, including doses, and a licensed agent can compare formularies, prior-authorization rules, and total annual cost. This is exactly what 1-800-MEDIGAP does at no charge. One toll-free call, 1-800-633-4427, connects you with a specialist who can review GLP-1 coverage, the new Bridge program, insulin caps, and Medigap options side by side.